Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 9Recurrence 4Breast Neoplasms 4Advanced Solid Tumors 4Solid Tumor 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Medical Oncology 2Lymphoma, Follicular 2Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Mesothelioma 1

Interventions

Rituximab 63Cyclophosphamide 57fludarabine phosphate 40fludarabine 37ibrutinib 28Lenalidomide 26Bendamustine Hydrochloride 26Filgrastim 20venetoclax 19obinutuzumab 17Bortezomib 17Peripheral Blood Stem Cell Transplantation 15Etoposide 12Biopsy 12Tacrolimus 11Specimen Handling 11Melphalan 11Interleukin-2 10tanespimycin 9Radiotherapy 9Cytarabine 9aldesleukin 8Whole-Body Irradiation 8Magnetic Resonance Spectroscopy 8idelalisib 7Vorinostat 7Paclitaxel 7Mycophenolic Acid 7Ipilimumab 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphocytic, Chronic, B-Cell × Itraconazole × Clear all
NCT06787131 2025-12-05

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Lomond Therapeutics Holdings, Inc.

Phase 1 Completed
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡